Verkstadsbolaget Xano Industri redovisar ett rörelseresultat om 87 miljoner kronor för det första kvartalet 2023, en stor nedgång jämfört med 146 miljoner från samma kvartal förra året.
Verkstadsbolaget Xano Industri redovisar ett rörelseresultat om 87 miljoner kronor för det första kvartalet 2023, en stor nedgång jämfört med 146 miljoner från samma kvartal förra året.
Verkstadsföretaget Xano har tecknat avtal om att sälja samtliga aktier i bolaget Xano Fastigheter Ljungarum som äger en industrifastighet i Jönköping. Köpeskillingen uppgår till 73 miljoner kronor kontant och medför en beräknad realisationsvinst om 65 miljoner kronor i fjärde kvartalet.
Börsveckan ger köpråd för Loomis och Thule i den senaste utgåvan. Tidningen lämnar rådet avvakta för Dometic och Sobi samt ger säljråd för Xano. Tidningen kommenterar även tre bolag, där tidigare råd kvarstår, innebärande köpråd för Instalco och Bredband2 samt avvakta för Neobo.
Xano förvärvar amerikanska Integrated Packaging Solutions (IPS) för 21 miljoner dollar. Det framgår av ett pressmeddelande.
Xano redovisar ett rörelseresultat för det andra kvartalet 2023 på 102 miljoner kronor.
Bolagets vd är dock positiv inför framtiden: "Goda möjligheter att stärka lönsamheten"
Verkstadsbolaget Xano Industri redovisar ett rörelseresultat om 87 miljoner kronor för det första kvartalet 2023, en stor nedgång jämfört med 146 miljoner från samma kvartal förra året.
Vi känner på pulsen från mässgolvet och visar på innovationsförmågan inom svensk tillverkningsindustri genom att besöka ett ...
Xano is the fastest way to build a backend with NO CODE Visit Xano: https://go.xano.co/3h6wvfg.
Introducing our most powerful duo yet… Xano x Adalo! Supercharge your Adalo app with the benefits of Xano's scalable no-code ...
Build a Supabase app with a Supabase-certified agency: https://www.thecalda.com/ Supabase: https://supabase.com/ Xano: ...
In today's episode of Category Visionaries, we speak with Prakash Chandran, Co-Founder and CEO of Xano, a No-Code backend development platform that's raised $5.4 Million in funding. Topics Discussed: Prakash’s background in tech and his time working at Google Why Prakash admires the CEO of AirBnb, and why he loves books that teach readers to shape their lives through action The lack of enterprise-ready tools for software engineering in the tech industry, and how Xano uses No-Code to allow people to build software without limits Why community-led growth is crucial when serving developers What tools Prakash used to shift and improve the messaging for Xano over time Favorite book: Atomic Habits: An Easy & Proven Way to Build Good Habits & Break Bad Ones
Summary: Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See the full write ups for today's episode at nascentmc.com/podcast Here are the highlights: Nirogacestat (Ogsiveo) For Desmoid Tumors: Nirogacestat is the first FDA-approved drug for treating progressing desmoid tumors in adults, offering a significant improvement in response rate compared to placebo in a major trial. Pirtobrutinib (Jaypirca) in CLL/SLL: The FDA granted accelerated approval for pirtobrutinib to treat adult patients with CLL/SLL who have undergone at least two prior therapies, with its effectiveness based on response rates from the BRUIN trial. Enfortumab Vedotin (Padcev) With Pembrolizumab (Keytruda) for Urothelial Cancer: The FDA is reviewing a combination treatment of enfortumab vedotin and pembrolizumab for urothelial cancer under priority review, showing significant improvement in survival rates compared to chemotherapy in a Phase 3 study. Lisocabtagene Maraleucel (Breyanzi) for CLL/SLL: The FDA is reviewing lisocabtagene maraleucel for expanded use in treating CLL/SLL patients who have relapsed after BTKi and BCL2i treatments, based on positive results from the TRANSCEND CLL 004 study. Xanomeline-trospium (KarXT) for Schizophrenia: The FDA is considering xanomeline-trospium for treating schizophrenia, with potential benefits over traditional treatments in reducing common antipsychotic side effects, based on the EMERGENT program results. Roflumilast Cream for Atopic Dermatitis: The FDA is reviewing roflumilast cream for treating atopic dermatitis in adults and children, supported by positive results from the INTEGUMENT-1 and INTEGUMENT-2 studies, with a potential for simplification in disease control. See the full write ups for today's episode at nascentmc.com/podcast Intro and outro music Garden Of Love by Pk jazz Collective
Join JJ and David as they discuss the latest in no-code on this week's episode of This Week in NoCode! This week we break down the latest no-code news including Softr launching their new AI capabilities and Xano's $10M funding round. We also recap the 2022 No Code Summit in Paris with special guest Kelly Claus, an experienced Bubble developer and designer. Kelly gives us exclusive behind-the-scenes details on the event, the highlights, challenges, and key takeaways. Later in the episode, we discuss the recent acquisition of We Love No Code by Toptal and what it signals about the growing no-code job market and enterprise adoption. 00:00 Intro 01:00 News: Softr AI 05:30 Xano Fundraise 06:00 Sponsor Segment: NoCodeDevs 16:15 No Code Summit Recap with Kelly 40:00 Acquisition: WeLoveNoCode and TopTail 46:30 Community Segment and Final Thoughts Lots of valuable insights into the world of no-code in this action-packed episode! Join our free NoCode Newsletter for news and discounts! Hire JJ and David to Build your MVP with NoCode. Learn Bubble.io from JJ Have Us Audit your Bubble.io Application. Follow us: https://twitter.com/JJEnglert https://twitter.com/cerealbuilder #nocode #lowcode #ai #podcast --- Send in a voice message: https://podcasters.spotify.com/pod/show/this-week-in-nocode/message
Xano is the fastest way to build a Backend without code or compromise. Website: www.xano.com Twitter: @nocodebackend
Prakash Chandran is the CEO and co-founder of Xano.com. A no-code solution. Prakash and I discuss developers' role in no-code solutions and how AI plays a role in the development cycle. No code does not mean no developers. It should be viewed as an assistant handling repetitive tasks while simplifying the business logic.As mentioned in this episodeXano.comXano on X (Twitter)(00:00) - Introduction (00:15) - Welcome Prakash Chandran (01:32) - The No-Code landscape (03:59) - Scaling Applications (07:02) - Data privacy and security (10:07) - Integration with existing applications (18:33) - AI is here to assist not replace (25:31) - Life after Google (29:55) - Focusing on the customer (33:19) - Reach out to Xano (33:57) - Xano on X (Twitter) (34:42) - Rate and review (35:28) - Support the podcast Please leave a review and show your support.https://lovethepodcast.com/compileswiftPlease find me on Mastodon@Compileswift@iosdev.space ★ Support this podcast ★
In this episode James and Glenn talk about building in public, James talks about using code to escape platform risk, and Glenn gives his updates on NoCodeKids with thoughts on subscription models and using Xano as an external database. What we're working on Glenn's SaaS is NoCode Kids, a learning management system to teach kids about no-code, built on Webflow. Kieran's SaaS is Yep.so, a super fast landing page builder and idea validation tool, built on Bubble. James' SaaS is Userloop, a customer feedback tool for Shopify merchants, built on Bubble.